Experience

• Corporate M&A

  • Konica Minolta, a Japanese multinational equipment and materials manufacturer operating in the healthcare and industrial industries, in the $600 million sale of its subsidiary, Ambry Genetics, to Tempus AI.
  • Tractor Supply Company in its acquisition of Allivet, an online pet pharmacy.
  • TPG and OneOncology in OneOncology’s acquisition of United Urology Group.
  • Symbiotic Capital, a global life science credit firm, in its inaugural fundraising of more than $600 million.
  • Clayton, Dubilier & Rice in its acquisition, together with TowerBrook, of R1 RCM, a provider of technology-driven solutions that impact the patient experience and financial performance of healthcare providers, at an enterprise value of $8.9 billion.
  • Hamilton Lane in the acquisition of a significant equity interest in Cosette Pharmaceuticals from Avista and its co-investors through funds managed by Hamilton Lane.
  • Valenz Health, a Kelso & Company portfolio company and platform of integrated cost containment and payment integrity solutions, in its acquisition of Healthcare Bluebook, a healthcare cost and quality navigation platform.
  • Clayton, Dubilier & Rice in its strategic partnership with Elevance Health, which will bring together certain care delivery and enablement assets of Elevance’s Carelon Health and CD&R portfolio companies, apree health and Millennium Physician Group.
  • The George Robert Rawlings Trust in the sale of the Rawlings Companies to New Mountain Capital Group L.P.
  • Konica Minolta, a Japanese multinational equipment and materials manufacturer operating in the healthcare and industrial industries, in the sale of its subsidiary Invicro to Calyx, a portfolio company of CapVest and leading technology-enabled provider.
  • Guggenheim Securities, as financial advisor to Gilead, in Gilead's $4.3 billion acquisition of biopharmaceutical company CymaBay.
  • Cynosure, a Clayton, Dubilier & Rice portfolio company and provider of medical aesthetic treatment systems, in its strategic combination with Lutronic, a provider of intelligent laser and energy-based systems.
  • Sawai and Sumitomo in the $210 million sale of its subsidiary Upsher-Smith Laboratories to Bora Pharmaceuticals.
  • Tarsadia Investments in the reorganization of Amneal Pharmaceuticals, a global pharmaceuticals company with a diverse portfolio of approximately 270 pharmaceutical products, which includes eliminating its umbrella partnership-C-corporation structure.
  • The Evercare Group in equity and debt financing aspects of its sale of a majority shareholding in CARE Hospitals to private equity funds managed by Blackstone.
  • J.P. Morgan Securities, as financial advisor to Olink, in the sale of Olink to Thermo Fisher, valuing Olink at $3.1 billion.
  • Clayton, Dubilier & Rice and Sharp in Sharp’s acquisition of Berkshire Sterile Manufacturing.
  • The Evercare Group, wholly owned by the Evercare Health Fund, in the sale of its majority interest in Nairobi Women’s Hospital to its founder and Group CEO, Dr. Samuel Maina Thenya.
  • TPG Growth in its acquisition of a majority stake in Crowe Healthcare Consulting, establishing it as an independent entity.
  • Mitsui in its agreement to tender its minority stake in Thorne to L Catterton in a take-private transaction with an aggregate value of approximately $680 million.
  • MTech Capital in its investment in digital health platform Peppy Health, as part of a Series B funding round.
  • Kelso & Company in its investment in Valenz.
  • TPG in its acquisition of a majority interest in OneOncology, a network of leading oncology practices, in a transaction valued at $2.1 billion.
  • StanCorp Financial Group in its acquisition of the Life & Disability business from Elevance Health.
  • Gentiva, a Clayton, Dubilier & Rice portfolio company and leading hospice, palliative, and personal care company, in its acquisition of Heartland hospice and home care.
  • Gedeon Richter, the specialty pharmaceutical company, in its acquisition of OC Distributors, an Ireland-based company holding the marketing and distribution rights of a number of women’s healthcare products.
  • J.P. Morgan Securities, as co-financial advisor to Horizon Therapeutics, a global biotechnology company, in its $28.5 billion sale to Amgen.
  • SVB Leerink as co-financial advisor to LHC Group in its sale to UnitedHealth Group’s Optum unit for approximately $5.4 billion.
  • The Evercare Group wholly owned by the Evercare Health Fund, in its sale of a majority shareholding in Metropolitan Hospital Holdings Limited to The Metro Group.
  • Deutsche Bank as financial advisor to Signify Health, a leading health care platform, in its $8 billion sale to CVS Health, a leading health solutions company.
  • Carlyle, in collaboration with its life sciences franchise Abingworth and their development company Launch Tx, in its investment of up to $170 million in biopharmaceutical company Opthea Limited.
  • CPP Investments as an investor in a single-asset continuation fund established by GHO Capital Partners, created to hold existing portfolio company Validant, a leading international provider of quality, compliance and regulatory affairs consulting to Biotech, Pharma and MedTech companies.
  • Clayton, Dubilier & Rice and TPG in their $4 billion take-private of Covetrus, a global animal-health technology and services company.
  • Clayton, Dubilier & Rice in its acquisition of a 60% interest in Humana’s Kindred at Home Hospice and Personal Care divisions, valued at $3.4 billion.
  • Carlyle in its $2 billion acquisition of Abingworth, a life sciences investment firm.
  • Resonetics, a leader in micro-manufacturing for the medical device and diagnostics equipment, in its acquisition of EaglePicher Medical Power, a medical device manufacturer.
  • Adams Street Partners as a member of a syndicate investing in a €500 million continuation fund established by G Square Healthcare Private Equity LLP to acquire three existing assets from G Square Capital I and G Square Capital II.
  • Leapfrog Investments in its sale of a 30% stake in Goodlife Pharmacies, a healthcare and retail pharmacy chain, to Eurapharma, the healthcare division of the CFAO Group.
  • Carestream Dental, a Clayton, Dubilier & Rice portfolio company and leading provider of dental technology, in the $600 million carve-out sale of its Scanning Technology business to Envista, a leading global dental products company.
  • Evercore, as financial advisor to Vocera Communications, in its sale to medical technologies company Stryker for a total enterprise value of approximately $3.09 billion.
  • Carlyle in its investment in Resonetics, a leader in micro-manufacturing for the medical device and diagnostics equipment industries, valuing the company at approximately $2.25 billion.
  • Carlyle in its acquisition of a majority stake in Saama, a leading AI-driven intelligent clinical cloud company that enables the life sciences industry to conduct faster and safer clinical developments and regulatory programs.
  • HealthEdge and its controlling shareholder, Blackstone, in the acquisition of Wellframe, a digital health management company.
  • Sun Life in its $2.475 billion acquisition of DentaQuest.
  • Blackstone in its investment in Medable, the leading cloud platform for patient-centered clinical research, valuing Medable at $2.1 billion.
  • HCA Healthcare, one of the nation’s leading provider of healthcare services, in its agreement to acquire the operations of five hospitals of Steward Health Care, the largest physician-led healthcare network.
  • HCA Healthcare, one of the nation’s leading provider of healthcare services, in its agreement to divest certain assets from its joint venture with Brookdale Health Care Services to LHC Group, a national provider of in-home healthcare.
  • A major investor in Envigo, a pharmaceutical and biotechnology research provider, in the sale of Envigo to Inotiv, a drug discovery and development contract research organization, for a total transaction value of approximately $545 million.
  • Life and Specialty Ventures in its collaboration with Cambia Health Solutions, including its acquisition of LifeMap, the reinsurance and administration of Cambia dental insurance policies, and Cambia’s acquisition of an equity stake in Life and Specialty Ventures.
  • TPG, Welsh, Carson, Anderson & Stowe and Kindred at Home in the sale of Kindred at Home to Humana, valuing Kindred at Home at $8.1 billion.
  • J.P. Morgan Securities, as financial advisor to PPD, in PPD's sale to Thermo Fisher for $17.4 billion in cash plus $3.5 billion of net debt.
  • Blackstone as a lead investor in the formation of Hydrogen Health.
  • Blackstone in its investment in Ginger, a leader in on-demand behavioral healthcare.
  • CPP Investments as lead investor in a $400 million Series C financing for insitro, a machine learning-driven drug discovery and development company.
  • Carlyle in the $2.5 billion merger of Grand Rounds and Doctor on Demand.
  • HCA Healthcare in its acquisition of a majority stake in Brookdale Health Care Services, the home health, hospice and outpatient therapy business of Brookdale Senior Living.
  • Carlyle in its $2.6 billion sale of MedRisk to CVC Capital Partners.
  • J.P. Morgan Securities, as financial advisor to AmerisourceBergen, in AmerisourceBergen’s acquisition of Alliance Healthcare from Walgreens Boots Alliance for approximately $6.5 billion in cash and stock.
  • HealthEdge and its controlling shareholder, Blackstone, in the acquisition of Altruista, a care management software company that delivers care management and population health management solutions that support value-based and person-centered care models.
  • Kelso & Company in the financing aspects of its acquisition of a majority stake in Refresh Mental Health.
  • Precision Medical Group in its $2.4 billion sale to Blackstone.
  • Kindred Healthcare in the sale of its RehabCare business line, a provider of contract therapy services in 43 states, to Select Rehabilitation, a leading provider of contract rehabilitation services.
  • Blackstone in its investment in Bright Health as part of a $500 million Series E financing round.
  • Carlyle in its majority investment in TriNetX, a leading global health research network optimizing clinical research to bring new therapies to market faster.
  • Morgan Stanley Capital Partners and Pathway Vet Alliance in the $2.7 billion sale of a majority stake in Pathway to TSG Consumer Partners.
  • LeapFrog Investments in its investment in MedGenome, a leading genetic diagnostics, research and data company focused on expanding access for populations in South Asia and other emerging markets, with operations in the U.S., India, Canada and Singapore.
  • Blackstone in its acquisition of HealthEdge, a leading technology business that delivers next generation Core Administrative Processing Systems (CAPS) solutions to healthcare businesses.
  • J.P. Morgan Securities, as financial advisor to Allergan, in the sale of Allergan to AbbVie for $63 billion in cash and stock and Allergan in its related divestitures of Brazikumab to AstraZeneca and Zenpep to Nestle.
  • Johnson & Johnson in its acquisition of TARIS, a biotechnology company specializing in the development of a novel drugs and delivery technologies for the treatment of cancer.
  • Clayton, Dubilier & Rice in its acquisition of Cynosure, a leader in medical aesthetics systems and technologies, from Hologic, a NASDAQ listed medical technology company primarily focused on women’s health.
  • Prudential Financial in its $2.35 billion acquisition of Assurance IQ.
  • Centerbridge Partners in its investment in GoHealth.
  • TPG Growth in its takeover of the existing assets of the Abraaj Group’s $1 billion Global Healthcare Fund. The deal saw Debevoise win the Specialist Deal Legal Advisor category at the Private Equity Africa Awards.
  • Bain Capital Private Equity and Diamond Castle in the sale of Beacon Health Options to Anthem.
  • CPP Investments in the $700 million growth equity financing of Sana Biotechnology, a U.S.-based biotech company focused on creating and delivering engineered cells as treatments for disease.
  • Prism, a leading retina surgeon practice, in its sale of a 60% stake to Quad-C Management.
  • Providence Service Corporation and LogistiCare in LogistiCare’s acquisition of Circulation, a provider of technology-enabled logistics solutions and analytics for managing non-emergency transportation across healthcare.
  • HCA Healthcare in its $1.5 billion acquisition of Mission Health, a nonprofit North Carolina health system.
  • Johnson & Johnson in its acquisition of Zarbee's Naturals, a leader in naturally-based healthcare products.

• Licensing, Development And Commercialization

  • Johnson & Johnson in its global co-development and commercialization agreement with Theravance Biopharma, relating to various compounds being developed for the treatment of inflammatory bowel disease, including Crohn's and ulcerative colitis.
  • Allergan in its global collaboration agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic.
  • Johnson & Johnson in its sale of Nizoral’s EMEA rights to STADA Arzneimittel AG; LATAM rights to Kramer Laboratories; and APAC rights to Alliance Pharmaceuticals Limited.
  • Galderma Pharma in its agreement with NovaBay Pharmaceuticals to develop and commercialize NovaBay's novel Aganocide drugs for major dermatological conditions.
  • Gen-Probe in its collaboration agreement with Pacific Biosciences of California in the research and development of third-generation DNA testing systems for use in disease diagnosis and blood screening.
  • Galderma Pharma in its licensing arrangement with Nuvo Pharmaceuticals (formerly ZARS Pharma) relating to the promotion and distribution of a topical anesthetic cream, Pliaglis, in North America and in the subsequent extension of that agreement to cover worldwide rights.
  • Hologic (formerly Gen-Probe) in its collaboration agreement with Pacific Biosciences of California in the research and development of third-generation DNA testing systems for use in disease diagnosis and blood screening.
  • Galderma Pharma in its worldwide development and commercialization agreement with Anika Therapeutics.

• Capital Markets And Finance

  • Clayton, Dubilier & Rice in the financing aspects of its bid for a controlling stake in Opella, the French-headquartered consumer healthcare company, valuing the company at c.€16 billion.
  • agilon health and Clayton, Dubilier & Rice in the $2 billion secondary offering and repurchase of shares of agilon health common stock.
  • Avenue Group, the Kenyan healthcare provider, in financing aspects of an investment by IFC.
  • agilon health and Clayton, Dubilier & Rice in the $587 million secondary offering of agilon health common stock.
  • Lannett Company in its $585 million comprehensive refinancing.
  • agilon health in its $1.2 billion initial public offering.
  • Vets First Choice in the financing aspects of its merger with the Henry Schein Animal Health business to create Covetrus, a new standalone public company.
  • Envision Healthcare in its $1.1 billion initial public offering of common stock.
  • Envision Healthcare, in its offering of $750 million of senior notes and in its $1.1 billion initial public offering of common stock.
  • Del Laboratories, a Kelso & Company portfolio company, in its exchange offer for floating rate secured notes.
  • AIG Altaris Health in senior financing relating to the equity recapitalization of Sparta Systems by Summit Partners and AIG Altaris.
  • Bear Stearns and Citigroup as lead underwriters in Endo Pharmaceuticals’ $868 million secondary offering of shares.

• Complex Litigations & Investigations

  • Certain former directors and shareholders of Purdue Pharma, regarding prescription opioid litigation in various fora across the country, including a federal multi-district litigation and actions brought by states attorneys general.
  • Medicredit, Inc., a subsidiary of Hospital Corporation of America, in achieving a landmark appellate ruling with the Fifth Circuit reversing an order certifying a class action under the Fair Debt Collection Practices Act.
  • A major New York health insurance company and its subsidiary in a qui tam suit regarding the alleged engagement of a half-billion dollar accounting fraud, obtaining a significant client victory in the form of a settlement and a complete voluntarily dismissal of the claims with prejudice.
  • Allergan in a successful dismissal, in the District of Massachusetts, of a qui tam complaint brought under the False Claims Act relating to the marketing of the pharmaceutical drug Namenda and in defeating nine nationwide class certifications of a putative class of third-party payors alleging violations of federal RICO statutes through fraudulent promotion of antidepressants.
  • HCA Healthcare as national strategic counsel in multiple class action violations of Telephone Consumer Protection Act, Fair Debt Collection Practices Act and state law recording statutes.
  • Memorial Sloan Kettering Cancer Center in reviewing and advising on conflicts-of-interest matters.
  • Bristol-Myers Squibb in defending against a $3.4 billion contract and tort claim by generic drug manufacturer, Apotex, winning a unanimous jury verdict of no liability.
  • The former CEO of Valeant Pharmaceuticals (now Bausch Health) in government investigations and civil securities class actions and other litigation relating to the company’s restatement and sales practices.
  • A multinational pharmaceutical company’s Board of Directors in internal investigation relating to product development, testing, and marketing.
  • A multinational healthcare company executive in investigations led by DOJ, the U.S. Attorney’s Office (E.D. Pa.), and U.S. Congress arising from consumer product recalls.

• Foreign Corrupt Practices Act

  • Independent FCPA consultant to Schering-Plough Corporation, appointed pursuant to consent of the Company and the SEC.
  • Multiple multinational pharmaceutical companies in internal investigations and provision of FCPA compliance advice.
  • A leading pharmaceutical company in parallel SEC and Department of Justice investigations of alleged earnings management/securities fraud, as well as in internal investigations and FCPA compliance advice.

• Data Strategy & Security

  • A technology-enabled healthcare company in responding to and containing a significant ransomware attack that disrupted certain company operations.
  • A major healthcare company in advice related to regulatory and governance issues around artificial intelligence.
  • Prudential Financial in cybersecurity and data privacy due diligence in its $2.35 billion acquisition of Assurance IQ.
  • A leading health insurance provider in advising on conflicts of interest and related government issues.
  • A Special Committee of the Board of Directors of a major U.S.-based pharmaceutical company in responding to a derivative demand letter broadly alleging misconduct, including securities violations, insider trading and fraud, arising in connection with the results of a clinical trial.

• Intellectual Property

  • GlaxoSmithKline in successfully prosecuting claims in a federal lawsuit alleging that a generic version of GSK’s ADVAIR inhaler made by Respirent Pharmaceuticals infringed GSK’s trade dress rights, following which Respirent made significant changes to the appearance of its product.
  • Merck KGaA in trademark infringement, trademark dilution, cybersquatting, false advertising and breach of contract litigation against Merck & Co. in the U.S. and 12 other countries.
  • JAB Holding Company, Pret Panera Holding Company and one of its senior executives in the successful dismissal of litigation in favor of arbitration arising from allegations of misappropriation of trade secrets, fraud, and unjust enrichment as a result of the director’s former position at a rival company.
  • Alcon Laboratories in the successful defense of a preliminary injunction sought by Pharmacia Corporation to enjoin the launch of Travatan.
  • Novartis and Bayer in obtaining preliminary injunctions against the illegal importation of foreign pet medicines.
  • Novartis in obtaining a preliminary injunction against the deceptively named Mylanta NightTime.
  • A major pharmaceutical company in patent infringement actions over effort to sell generic versions of products under purported Part IV certifications.

• International Dispute Resolution

  • A major pharmaceutical company with advice at board-level concerning worldwide supply chain issues, including delay and quality concerns resulting in severe disruption caused to its global vaccines business, resulting in a successful settlement avoiding lengthy arbitration proceedings.
  • A global pharmaceutical company in litigation alleging material breaches and unilateral termination of a commercial supply agreement for the development and manufacture of a vaccine.
  • One of the world’s largest pharmaceutical companies in an AAA arbitration under English law relating to a collaboration agreement to develop new drugs.
  • A leading French pharmaceutical manufacturer in settling on favorable terms a dispute arising out of a distribution agreement with a Moroccan company.
  • IMS Health Incorporated and its Latin American affiliates in a Spanish-language ICC arbitration relating to an alleged breach in Brazil, Mexico and certain other Latin American jurisdictions of a contract governed by Argentine law.
  • A leading pharmaceutical manufacturer in arbitration/litigation against an international paper products manufacturer concerning joint marketing agreements in France.
  • A multinational pharmaceutical company in obtaining a successful defense verdict in $3.5 billion contract dispute.
  • A major, global pharmaceutical company in an arbitration involving cross-licenses and product development.
  • A major global pharmaceutical company in various claims relating to patent issues.
  • A major, global pharmaceutical company in a dispute involving distribution of products in China.